{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:51:01Z","timestamp":1784843461198,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Chemotherapy for acute lymphoblastic leukemia (ALL) patients is complex and intense, resulting in a high readmission rate. We aimed to identify the incidence, causes, and risk factors of readmission following inpatient chemotherapy among ALL patients, using 2016 National Readmission Database. We applied three different definitions of 30-day readmission: (1) nonelective readmission based on readmission type, (2) unplanned readmission defined by CMS, and (3) unintentional readmission, combining (1) and (2). We used unweighted multivariable Poisson regression with robust variance estimates for risk factors analysis, including patient-, hospital-, and admission-related characteristics. Percentage for nonelective, unplanned, and unintentional readmission were 33.3%, 22.4%, and 18.5%, respectively. The top three causes for unplanned readmissions were neutropenia\/agranulocytosis (27.8%), septicemia (15.3%), and pancytopenia (11.5%). Risk ratios for unintentional readmission were 1.21 (1.08\u20131.36) for nonelective vs. elective admission, 1.19 (1.06\u20131.33) for public vs. private insurance enrollees, 0.96 (0.95\u20130.98) for each day of hospital stay, 0.77 (0.62\u20130.95) for large teaching and 0.87 (0.70\u20131.08) for small teaching vs. nonteaching hospitals. Possible strategies to reduce readmission among ALL patients could be shortening the gap in quality of care among teaching vs. non-teaching hospitals, understanding the difference between privately vs. publicly insured patients, and avoiding aggressive discharge after chemotherapy.<\/jats:p>","DOI":"10.3390\/healthcare8040401","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T08:59:22Z","timestamp":1602665962000},"page":"401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and Risk Factors for 30-Day Readmission after Inpatient Chemotherapy among Acute Lymphoblastic Leukemia Patients"],"prefix":"10.3390","volume":"8","author":[{"given":"Phuong T.","family":"Tran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA"},{"name":"Faculty of Pharmacy, Ho Chi Minh City University of Technology\u2014HUTECH, Ho Chi Minh City 700000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Slayton","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Dalal","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-1021","authenticated-orcid":false,"given":"Joshua","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (2020, April 01). Definition of Acute Lymphoblastic Leukemia\u2014NCI Dictionary of Cancer Terms, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/acute-lymphoblastic-leukemia."},{"key":"ref_2","unstructured":"American Cancer Society (2020, April 01). What Is Acute Lymphocytic Leukemia (ALL)? Acute Lymphocytic Leukemia (ALL). Available online: https:\/\/www.cancer.org\/cancer\/acute-lymphocytic-leukemia\/about\/what-is-all.html."},{"key":"ref_3","unstructured":"National Cancer Institute (2020, April 01). SEER Cancer Stat Facts: Acute Lymphocytic Leukemia, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html."},{"key":"ref_4","unstructured":"National Comprehensive Cancer Network (2020, April 01). NCCN Guidlines Version 5.2017 Acute Lymphoblastic Leukemia. Available online: https:\/\/oncolife.com.ua\/doc\/nccn\/Acute_Lymphoblastic_Leukemia.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1200\/JCO.2008.20.8959","article-title":"Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: A report from the children\u2019s oncology group","volume":"27","author":"Nachman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cam4.583","article-title":"A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia","volume":"5","author":"Kaul","year":"2016","journal-title":"Cancer Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MPH.0000000000000559","article-title":"The Effects of Hospital Length of Stay on Readmissions for Children with Newly Diagnosed Acute Lymphoblastic Leukemia","volume":"38","author":"Wedekind","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e196476","DOI":"10.1001\/jamanetworkopen.2019.6476","article-title":"Factors Associated with Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals","volume":"2","author":"Dhakal","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_9","unstructured":"Medicare.gov (2020, April 01). 30-Day Death and Readmission Measures Data, Available online: https:\/\/www.medicare.gov\/hospitalcompare\/Data\/30-day-measures.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2019.11.023","article-title":"Acute readmission following deep brain stimulation surgery for Parkinson\u2019s disease: A nationwide analysis","volume":"70","author":"Schneider","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.athoracsur.2019.05.071","article-title":"National Study of Index and Readmission Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients with Renal Disease","volume":"109","author":"Sanaiha","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bilal, M., Samuel, R., Khalil, M.K., Singh, S., Parupdui, S., and Abougergi, M.S. (2020). Nonvariceal upper GI hemorrhage after percutaneous coronary intervention for acute myocardial infarction: A national analysis over 11 months. Gastrointest Endosc.","DOI":"10.1016\/j.gie.2020.01.039"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Crispo, J.A.G., Thibault, D.P., Fortin, Y., Krewski, D., and Willis, A.W. (2018). Association between medication-related adverse events and non-elective readmission in acute ischemic stroke. BMC Neurol., 18.","DOI":"10.1186\/s12883-018-1195-0"},{"key":"ref_14","unstructured":"Healthcare Cost and Utilization Project (2020, April 01). Overview of the Nationwide Readmissions Database, Available online: https:\/\/www.hcup-us.ahrq.gov\/nrdoverview.jsp."},{"key":"ref_15","unstructured":"The Agency for Healthcare Research and Quality (2020, October 01). Admission type, Available online: https:\/\/ushik.ahrq.gov\/ViewItemDetails?system=mdr&itemKey=74569000."},{"key":"ref_16","unstructured":"Centers for Medicare & Medicaid Services (2020, April 01). Measures Inventory Tool: 30-Day Unplanned Readmissions for Cancer Patients, Available online: https:\/\/cmit.cms.gov\/CMIT_public\/ViewMeasure?MeasureId=6030."},{"key":"ref_17","first-page":"138","article-title":"Management of acute lymphoblastic leukemia in young adults","volume":"16","author":"Muffly","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_19","unstructured":"Healthcare Cost and Utilization Project (2020, July 19). Overview of Disease Severity Measures Disseminated with the Nationwide Inpatient Sample (NIS) and Kids\u2019 Inpatient Database (KID), Available online: https:\/\/hcup-us.ahrq.gov\/db\/nation\/nis\/OverviewofSeveritySystems.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.21037\/atm.2018.08.13","article-title":"%ggBaseline: A SAS macro for analyzing and reporting baseline characteristics automatically in medical research","volume":"6","author":"Gu","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, W., Qian, L., Shi, J., and Franklin, M. (2018). Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med. Res. Methodol., 18.","DOI":"10.1186\/s12874-018-0519-5"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/oxfordjournals.aje.a114458","article-title":"The effect of misclassification of disease status in follow-up studies: Implications for selecting disease classification criteria","volume":"124","author":"White","year":"1986","journal-title":"Am. J. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.leukres.2018.06.013","article-title":"Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia","volume":"71","author":"Warrick","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/pbc.21553","article-title":"Risk factors for readmission after initial diagnosis in children with acute lymphoblastic leukemia","volume":"51","author":"Slone","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pulte, D., Jansen, L., Gondos, A., Katalinic, A., Barnes, B., Ressing, M., Holleczek, B., Eberle, A., Brenner, H., and Group, G.C.S.W. (2014). Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085554"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Barros, A.J., and Hirakata, V.N. (2003). Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Med. Res. Methodol., 3.","DOI":"10.1186\/1471-2288-3-21"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/8\/4\/401\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:21:14Z","timestamp":1760178074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/8\/4\/401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["healthcare8040401"],"URL":"https:\/\/doi.org\/10.3390\/healthcare8040401","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]}}}